Fangsheng Pharmaceutical announced that Jianmeng Pharmaceutical, a wholly-owned subsidiary of the company, has received the “Drug Registration Certificate” approved and issued by the State Drug Administration, and the innovative traditional Chinese medicine medicine medicine blood nourishment and pain relief granules independently developed by the company have obtained a drug approval number and can be produced. This medicine is based on the addition and subtraction of “soup”. It can replenish qi and nourish blood, relieve wind and pain, and is suitable for frequent tension-type headaches. It has not previously been sold domestically or internationally. The approval of this drug has further enriched the company's innovative Chinese medicine product pipeline, which is conducive to accelerating the company's development strategy. However, the specific sales situation is affected by various factors and will not have a significant impact on the company's performance in the short term.

Fangsheng Pharmaceutical announced that Jianmeng Pharmaceutical, a wholly-owned subsidiary of the company, has received the “Drug Registration Certificate” approved and issued by the State Drug Administration, and the innovative traditional Chinese medicine medicine medicine blood nourishment and pain relief granules independently developed by the company have obtained a drug approval number and can be produced. This medicine is based on the addition and subtraction of “soup”. It can replenish qi and nourish blood, relieve wind and pain, and is suitable for frequent tension-type headaches. It has not previously been sold domestically or internationally. The approval of this drug has further enriched the company's innovative Chinese medicine product pipeline, which is conducive to accelerating the company's development strategy. However, the specific sales situation is affected by various factors and will not have a significant impact on the company's performance in the short term.